Nucleic-Acid Based Therapeutics (Technical Insights)

Strategic Portfolio Management

Regular Price: USD 4,950

Special Price USD 3,465

30% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 3,465

PAY BY INVOICE

Be the first to review this product

The nucleic acid drugs sector consists of three major sub-sectors--aptamer therapeutics, antisense therapeutics, and RNA interference. Recent partnerships and alliances show an amalgamation of collaborations for discovery platforms and delivery technologies as well as drug entities. This report analyzes the R&D portfolio trends in these sub-sectors and then uses the Analytical Hierarchy Process (AHP) to prioritize different options that can be executed to design a strategic R&D portfolio,which showcases a company’s innovation capacity and also leads to higher credibility among investors. Portfolio options have been prioritized on a disease basis which is the one commonly followed by both big pharmaceuticals and biotech companies.

Table of Contents

Nucleic-Acid Based Therapeutics (Technical Insights), Nucleic-Acid Based TherapeuticsNucleic-Acid Based TherapeuticsNucleic-Acid Based Therapeutics




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 15-Dec-17

Region : Global

Release Date : 08-Dec-17

Region : Global

Release Date : 08-Dec-17

Region : Global

Release Date : 01-Dec-17

Region : Global

Release Date : 29-Nov-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.